Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters









Database
Language
Publication year range
1.
Maternal and Infant Bone Mineral Density 1 Year After Delivery in a Randomized, Controlled Trial of Maternal Tenofovir Disoproxil Fumarate to Prevent Mother-to-child Transmission of Hepatitis B Virus.
Salvadori, Nicolas; Fan, Bo; Teeyasoontranon, Waralee; Ngo-Giang-Huong, Nicole; Phanomcheong, Siriluk; Luvira, Anita; Puangsombat, Achara; Suwannarat, Arunrat; Srirompotong, Ussanee; Putiyanun, Chaiwat; Cressey, Tim R; Decker, Luc; Khamduang, Woottichai; Harrison, Linda; Tierney, Camlin; Shepherd, John A; Kourtis, Athena P; Bulterys, Marc; Siberry, George K; Jourdain, Gonzague.
Clin Infect Dis ; 69(1): 144-146, 2019 06 18.
Article in English | MEDLINE | ID: mdl-30924492

ABSTRACT

In a randomized, double-blind, placebo-controlled trial of tenofovir disoproxil fumarate (TDF) use from 28 weeks gestational age to 2 months postpartum to prevent mother-to-child transmission of hepatitis B virus, there was no significant effect of maternal TDF use on maternal or infant bone mineral density 1 year after delivery/birth. Clinical Trials Registration. NCT01745822.


Subject(s)
Antiviral Agents/therapeutic use , Bone Density/drug effects , Hepatitis B/drug therapy , Infectious Disease Transmission, Vertical/prevention & control , Tenofovir/therapeutic use , Adult , Double-Blind Method , Female , Gestational Age , Hepatitis B virus , Humans , Infant , Male , Postpartum Period , Pregnancy , Pregnancy Complications, Infectious/prevention & control , Pregnancy Complications, Infectious/virology , Viral Load/drug effects , Young Adult
SEND TO:
Email
Export
Print
RSS
XML
SELECTION OF CITATIONS
SEARCH DETAIL